Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Merck

Pharmaceutical sales up 6% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
2Q Revenues: $ $10.5 billion (+5%)
2Q Earnings: $1.7 billion (-12%)
YTD Revenues: $20.5 billion (+6%)
YTD Earnings: $2.5 billion (-30%)
Comments: Pharmaceutical sales increased 6% in the quarter to $9.3 billion, driven by growth in oncology, vaccines and hospital acute care, partially offset by lower sales in virology and the ongoing impacts of the loss of market exclusivity for several products. KEYTRUDA sales were up 89% to $1.7 billion. JANUVIA sales were $1.5 billion, up 2%. GARDASIL sales were $608 million, up 30%. PROQUAD, M-M-R II and VARIVAX sales were up 7% to $426 million.  BRIDION sales were up 48% to $240 million. ZETIA / VYTORIN sales were down 31% to $381 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters